Can we use hydroxychloroquine to treat COVID-19 now?

Int J Antimicrob Agents. 2021 Jan;57(1):106173. doi: 10.1016/j.ijantimicag.2020.106173.

Authors

Jun Chen¹, Danping Liu¹, Lin Yin², Lijun Zhang², Hongzhou Lu³

Affiliations

¹ Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
² Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
³ Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China. Electronic address: luhongzhou@fudan.edu.cn.

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Antimalarials / therapeutic use
Antiviral Agents / therapeutic use*
Azithromycin / therapeutic use*
COVID-19 / virology
COVID-19 Drug Treatment*
Clinical Trials as Topic
Drug Combinations
Drug Repositioning
Humans
Hydroxychloroquine / therapeutic use*
Indoles / therapeutic use
Interferon-alpha / therapeutic use
Lopinavir / therapeutic use
Ritonavir / therapeutic use
SARS-CoV-2 / pathogenicity*
Uncertainty

Substances

Anti-Bacterial Agents
Antimalarials
Antiviral Agents
Drug Combinations
Indoles
Interferon-alpha
lopinavir-ritonavir drug combination
Lopinavir
Hydroxychloroquine
Azithromycin
umifenovir
Ritonavir